PLATINUM2024

International Cancer Advocacy Network

The Virtual Lifeline for Proactive Cancer Patients

aka ICAN (trade name on file with AZ Secretary of State; USPTO trademark); Exon 20 Group   |   Phoenix, AZ   |  https://askican.org/

Mission

ICAN provides direct patient navigation services, molecular profiling and clinical trials advocacy, research services, and public education about the anticancer drug pipeline. ICAN focuses on Stage IV patients, spanning the gamut of cancer types-from the most commonly diagnosed solid tumors to the rarest of hematological malignancies and synchronous cancers. ICAN assists patients in accessing drugs via expanded access programs. The Exon 20 Group's grants ($300,000 in 2023) are targeted to specific cancer research laboratories. The organization specializes in complex cases, rare cancers, and cancers of unknown primary. ICAN handles patients with oncology teams in major cancer centers as well as patients who are uninsured, underinsured, and who have been under-served.

Notes from the nonprofit

Volunteer-Driven: In the words of a CBS local news anchor in 2013 at an event honoring our CEO and other leaders in the nonprofit world, ICAN had transformed in 2008 "from a traditional nonprofit to a global volunteer colossus." ICAN estimates that the wealth of volunteer talent has amounted to an in-kind donation approaching $5.7 million. To understand ICAN is to understand its vast global network of high quality volunteers who assist us in more than 30 separate areas. Health Equity: Since 2010, our volunteers and Nat'l Board Members have represented every race and ethnicity. The patients/care partners we serve + our ICAN Named Programs reflect that robust diversity as well. Complete Transparency: ICAN is very proud of its volunteer base which runs 100% of special events, with no staff involvement (staff is 100% devoted to Patient Services). ICAN's Board Governance internal audit group pre-approves every Patient Services, special event, management, and fundraising expense.

Ruling year info

1996

President and CEO

Ms. Marcia Karen Horn JD

Main address

Friends of ICAN 27 West Morten Avenue

Phoenix, AZ 85021-7246 USA

Show more contact info

Formerly known as

IFADD, International Foundation for Anticancer Drug Discovery

EIN

86-0818253

NTEE code info

Alliance/Advocacy Organizations (G01)

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2022, 2021 and 2020.
Register now

Communication

Programs and results

What we aim to solve

SOURCE: Self-reported by organization

The essential need that ICAN is addressing is the optimal positioning, through world class information resources as well as our network of clinicians and researchers, of metastatic cancer patients toward the twin goals of best possible survival and the highest quality of life. ICAN aims to extend the lives of Stage IV cancer patients with the highest achievable quality of life, propelling each of our patients into the top one percent of all proactive cancer patients and thus leaving no stone unturned in their battles for life. Over the next five years, ICAN intends to pursue this overarching goal through the furtherance of our direct patient navigation and health technology initiatives, our research initiatives, and our 24/7/365 Patient Program Services, stressing every tool possible in the battle defeat cancer which is a complex molecular and metabolic disorder that the global oncology community is yet to fully understand.

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Personalized Medicine Cancer Case Navigation Programs

A complete description of these Programs is found on https://askican.org/

ICAN has unlimited needs in this area based on patient demand.
For additional information regarding specific budgets and fundraising goals, please call us at 602-618-0183.

Population(s) Served
Adults
Ethnic and racial groups

ICAN owns and manages the Biomarker Collaborative, the MET Crusaders, the Exon 20 Group, and the PD-L1 Amplifieds, all biomarker support groups and all multi-stakeholder organizations.

ICAN's Rare Cancer Advocacy Programs, in coordination with our Molecular Tumor Board and network of clinicians and scientists worldwide, provide customized advocacy based on the molecular profiling and comprehensive biomarker testing results of the patients we serve.

ICAN has unlimited needs in serving our patients who have been diagnosed with rare blood cancers and blood disorders or rare solid tumors or sarcoma.

ICAN has a particular interest in DIPG, diffuse intrinsic pontine glioma (children and adolescents) and thanks to the generosity of one of our leaders, has awarded a grant, in memory of one of our patients, to the Michelle Monje Laboratory at Stanford University.

For additional information regarding specific budgets and fundraising goals, please call us at 602-618-0183.

Population(s) Served
Adults
Ethnic and racial groups

ICAN educates patients, physicians, and the public on matters of patient safety, access to care, access to oral therapies, prior authorization, and other issues of importance to those battling chronic and lethal disease. There are eight topics in the current repertoire of various state legislatures revolving around patient access issues.

ICAN has ambitious goals in the public education area based on the needs of the patients and oncology teams with whom we work closely to protect the important value of shared decision-making.

For additional information regarding specific budgets and fundraising goals, please call us at 602-618-0183.

Population(s) Served
Adults
Ethnic and racial groups

The Exon 20 Group was founded in March 2017 by Kevin M. Hanlon (of blessed memory) and his brother Robert T. Hanlon, PhD. Dr. Hanlon remains chair and co-founder. The Exon 20 Group, https://exon20group.org/, is a global multistakeholder coalition of top thoracic and medical oncologists; exon 20 insertion patients; lung cancer patient advocates; molecular biologists and molecular pathologists; leading laboratories; pharmaceutical companies and biotech companies; and molecular profiling companies.

The Exon 20 Group has awarded grants to The Broad Institute at MIT/Harvard, the John V. Heymach, MD, PhD Laboratory at the University of Texas MD Anderson Cancer Center, and the Roderick O'Connor Laboratory at the University of Pennsylvania, among other grants. ICAN is pleased that its grant to the Matthew Meyerson, MD, PhD Laboratory at the Broad Institute over two years played a role in the development of an exon 20 oral inhibitor which entered Phase 1 in 2021.

Population(s) Served
Adults
People of Asian descent

Where we work

Awards

Distinguished Achievements Award to Marcia Horn 1999

Arizona State University Cancer Research Institute

Leadership Award to Marcia Horn based on her efforts to double the ASU Cancer Research Institute's budget through a successful legislative appropriation several years earlier 2001

Arizona State University Campaign for Leadership

Renaissance Woman Angel Award to Marcia Horn 2003

Art Renaissance Initiative

2012 Health Care Heroes Award Finalist 2012

Phoenix Business Journal

2013 Leader of Distinction Finalist 2013

ONE, Organization of Nonprofit Executives

Marcia Horn named Chairman of Patient Engagement Community 2013

DIA, Drug Information Association

ICAN was the only cancer charity recommended for professional cancer patient advocacy in the new book "Outliving Cancer" 2013

Robert Nagourney, MD, Rational Therapeutics

ICAN CEO named to IRB 2013

Banner MD Anderson Institutional Review Board (Oncology Panel)

The ICAN breast cancer patient's remission endures to this day (John Link, MD, medical oncologist) 2011

Profile in Newsweek regarding complete remission of ICAN metatstatic cancer patient

TOPs Finalist Award to ICAN's CEO 2015

Horace Rumpole Inn of Court

CEO named to this Committee with 10-year term 2015

SWOG Early Therapeutics/Rare Cancers Committee

CEO named as one of 19 patient advocates where one advocate participates in each MTB session 2016

ASCO TAPUR Study Molecular Tumor Board

CEO named as U.S. Patient Advocate 2014

Stand Up 2 Cancer MEDOCC Dream Team

CEO named as one of two Patient Advocates 2017

Stand Up 2 Cancer INTime Lung Cancer Dream Team

CEO as Member, often with Primary Reviewer status 2017

Banner Health Arizona Institutional Review Board

CEO as a member of the Patient Advocate Committee 2019

Alliance for Clinical Trials in Oncology

Top Rated Health Care and Top Rated Cancer Organization for 13 years 2023

Great Nonprofits

CEO named one of the research advocates on behalf of UT Southwestern-MD Anderson Cancer Center SPORE 2017

National Cancer Institute Lung SPORE

CEO elected Vice President 2021

Biomarker Collaborative

CEO elected to Board of Directors 2021

NTRKers Foundation Board of Directors

See conference posters on request 2021

The Exon 20 Group is mentioned by clinicians and industry members

See journal articles on request 2021

The Exon 20 Group is cited in journal articles authored by prominent research oncologists

Tournament Beneficiary 2022

ICAN is selected as one of 70 charity tournaments sponsored by Liberty Mutual Insurance, 2010-2022

Award for ICAN's Newsletter 2015

Constant Contact

HonCode 2020

Honor Code certification for health-related website information

Member, SCLC Committee 2024

IASLC Rare Tumors Committee

Affiliations & memberships

National Lung Cancer Round Table 2018

Biomarker Collaborative--our CEO is Vice President 2021

Charity Navigator's Consultative Council of Nonprofit Leaders (CCNL) 2022

From Testing to Targeted Therapies (FT3) Membership 2022

IASLC Rare Tumors Committee 2024

Dava Oncology, invited to provide patient advocate perspective 2024

Continuing Protocl Reviews, Informed Consent Reviews, multiple biopharma companies 2015

Our results

SOURCE: Self-reported by organization

How does this organization measure their results? It's a hard question but an important one.

Number of advocate or trained spokesperson citations in the media

This metric is no longer tracked.
Totals By Year
Population(s) Served

Adults, Children and youth, Multiracial people, People with diseases and illnesses

Related Program

Public Policy Advocacy Programs

Type of Metric

Context - describing the issue we work on

Direction of Success

Holding steady

Context Notes

ICAN's CEO is one of the leading voices in state legislative affairs & coalitions re the issue of access to personalized medicine. We are involved in reimbursement and coverage issues.

Number of briefings or presentations held

This metric is no longer tracked.
Totals By Year
Population(s) Served

Adults

Related Program

Personalized Medicine Cancer Case Navigation Programs

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Context Notes

ICAN's staff, boards, & medical and scientific councils, brief various stakeholders and selected medical affairs/scientists audiences on precision oncology issues. (Virtual in 2020 and 2021)

Number of stakeholders/stakeholder groups with whom communication has been achieved and expectations shared

This metric is no longer tracked.
Totals By Year
Population(s) Served

Adults

Related Program

Personalized Medicine Cancer Case Navigation Programs

Type of Metric

Output - describing our activities and reach

Direction of Success

Holding steady

Context Notes

ICAN works with a wide range of stakeholders in our multi-stakeholder organizations as well as our coalition and collaboration efforts with other orgs in the rare cancer and solid tumor spaces.

Number of hours of coaching

This metric is no longer tracked.
Totals By Year
Population(s) Served

Adults

Related Program

Personalized Medicine Cancer Case Navigation Programs

Type of Metric

Context - describing the issue we work on

Direction of Success

Holding steady

Context Notes

Molecular Profiling and Clinical Trials Matching Services, regarding ordering, interpretation, triaging for therapeutic sequencing purposes. The metric we use for this is Holding Steady.

Hours of consulting time accessed

This metric is no longer tracked.
Totals By Year
Population(s) Served

Adults, Caregivers, Multiracial people, People with diseases and illnesses

Related Program

Personalized Medicine Cancer Case Navigation Programs

Type of Metric

Output - describing our activities and reach

Direction of Success

Holding steady

Context Notes

Stakeholders across the research continuum seeking our work on patient-centricity and patient-focused drug development. Because of our 24/7/365 patient navigation services, we have to limit our time.

Hours of mentoring

This metric is no longer tracked.
Totals By Year
Population(s) Served

Adults, LGBTQ people, Ethnic and racial groups, Social and economic status, Work status and occupations

Related Program

Public Policy Advocacy Programs

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Context Notes

Patient Access Advocacy Team mentoring of under-resourced patients in the Linda Jenckes Health Care Public Policy Program at ICAN and other programs at ICAN.

Number of testimonies offered

This metric is no longer tracked.
Totals By Year
Population(s) Served

Adults

Related Program

Personalized Medicine Cancer Case Navigation Programs

Type of Metric

Outcome - describing the effects on people or issues

Direction of Success

Increasing

Context Notes

These detailed testimonies do not include website testimonials, spontaneous emailed testimonials from patients, patient families, scientists, and clinicians, received on a near daily basis at ICAN.

Number of External Organizations and Coalitions with which ICAN Leaders are Actively Engaged that Benefit ICAN's Personalized Medicine Programs

This metric is no longer tracked.
Totals By Year
Population(s) Served

Adults

Related Program

Personalized Medicine Cancer Case Navigation Programs

Type of Metric

Output - describing our activities and reach

Direction of Success

Holding steady

Context Notes

ICAN's CEO, Chair of the Biomarkers Council, & Director of Governmental Affairs are engaged in BIO, AfPA, ASBM, Stand Up to Cancer Dream Teams, SWOG, IASLC, PCORI, & ASCO Molecular Tumor Board etc.

Number of published articles, podcasts, and/or posters presented at conferences and conference recognition

This metric is no longer tracked.
Totals By Year
Population(s) Served

Adults

Related Program

Personalized Medicine Cancer Case Navigation Programs

Type of Metric

Outcome - describing the effects on people or issues

Direction of Success

Holding steady

Context Notes

This live and virtual presentation metric applies to ICAN's Personalized Medicine Cancer Case Navigation Programs as well as our multi-stakeholder international coalition, the Exon 20 Group.

Number of Board Governance Documents Added to the ICAN Governance Project

This metric is no longer tracked.
Totals By Year
Population(s) Served

Adults

Related Program

Personalized Medicine Cancer Case Navigation Programs

Type of Metric

Context - describing the issue we work on

Direction of Success

Holding steady

Context Notes

ICAN's Board specializes in board governance issues/docs, and our leadership has mentored on this issue (nonprofit board policies) as well as lectured on these issues to other nonprofit executives.

Number of policymakers or candidates reached

This metric is no longer tracked.
Totals By Year
Population(s) Served

Children and youth, Adults, Ethnic and racial groups

Related Program

Public Policy Advocacy Programs

Type of Metric

Output - describing our activities and reach

Direction of Success

Holding steady

Context Notes

State Legislators/Members of Congress/staffs . ICAN has no involvement w/political candidates or campaigns but advocates on patient access issues w/customized letter writing/testimonies.

Molecular Tumor Boards/Advisory Boards/Protocol Reviews

This metric is no longer tracked.
Totals By Year
Related Program

Personalized Medicine Cancer Case Navigation Programs

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Our Sustainable Development Goals

SOURCE: Self-reported by organization

Learn more about Sustainable Development Goals.

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

It is important to note that ICAN has never engaged in a national or state telemarketing fundraising campaign or conducted a national mailing campaign or a state mass mailing or even targeted mailing campaign. And we plan to keep it that way. The overwhelming majority of our revenues come from the spontaneous gifts of grateful patients and their families.

ICAN specifically is working toward:

1) Providing concrete strategic options for Stage IV patients across the U.S. and abroad who have been told by their oncologists that no additional options were available either from the standard drug pipeline or in clinical trials (or through another treatment modality such as surgery, radiation oncology, interventional radiology, or medical oncology);

2) Expanding the focus of our research and technology initiatives;

3) Expanding our extensive local, national, and global network of highly talented volunteers, who are devoted to optimizing patient outcomes by engaging industry, academia, government, and regulatory affairs experts across relevant issues and platforms; and

4) Converting the rare cancer driven by an exon 20 insertion mutation from a lethal to a chronic, maintenance disease through the organization's special multi-stakeholder global coalition and biomarker support group called the Exon 20 Group, reaching patients in 72 countries. [Based on the work of the John V. Heymach, MD, PhD Laboratory at The University of Texas MD Anderson Cancer Center, HER2 exon 20 insertions and EGFR exon 20 insertions are each found in approximately 25 cancers, including lung cancer.]

ICAN's strategies for making this happen include building our international, multi-stakeholder working group, the Exon 20 Group; building auxiliary advisory councils and Friends of ICAN support groups. ICAN will also be focusing on enhanced fund development and planned giving in addition to more robust special event fundraising efforts.

ICAN also looks to the tremendous diversity and global influence among members of its boards, councils, committees, and worldwide volunteer network to achieve success:

ICAN's global network consists of patient advocates, research advocates, research volunteers, nursing volunteers, and event volunteers.

ICAN's Angel Buddy peer-to-peer counseling program pairs patients with one to four different ICAN patient/family mentors (depending on the specific case and the needs of the patient).

ICAN, comprised of a multiplicity of top notch stakeholders, is testing different molecular tumor board formats to fit the needs of a diversity of patients and clinicians.

ICAN's capabilities for doing this include an impressive local, national and indeed global volunteer network and brain trust of both visionaries and achievers. ICAN is a cancer advocacy organization packing a national punch with a global reach.

Many of our supporters have asked us how we have managed to have as our most recent 990 "ratio" a coveted 94% of our Total Expenses allocated to Patient Program Services. It's easy. Management/General is handled by tremendous long-standing volunteers who've been with us since 2009. At the beginning of the recession in 2008, we knew that we could not continue operating with the normal nonprofit paradigm. Our CEO went to the Board and said that we had to implement a new paradigm of recruiting a global volunteer network of highly talented people who could fill in for the traditional staff who departed ICAN at the start of the recession. We thus embarked on one of the most aggressive campaigns ever to recruit top flight volunteer talent. And Pat McReynolds, a local CBS anchor said in March, 2013, introducing our CEO who was a finalist in the Organization of Nonprofit Executives' Leader of the Year awards: "Marcia Horn has taken a traditional nonprofit and transformed it into a global volunteer colossus."

Here are the areas where we secured volunteer talent to replace previously paid staff:

1) Research Admin Services--led by seasoned admin/tech/citation professionals since 2009
2) Research Volunteers--highly-educated research graduate students, retirees, nursing professionals, and biopharma industry veterans--several of whom have been with us since 2009
3) Special Events--100 percent of sponsorship recruitment and tournament foursomes procurement is handled by our board and event leadership--whether our the Liberty Mutual Invitational in Scottsdale, or our Swing fore Life Golf Invitational in Fayetteville, New York, or a planned event in New Hampshire--thus allowing ICAN to concentrate on its sole mission of improving patient outcomes. Our Texas Board of Advisors, led by Chuck Clayton, handles every detail of Poker and Casino events.
4) Special Projects Administration--we are blessed with incredible committees who handle every logistical detail
5) Fund Development--handled by our lay leadership who volunteer their time and talents
6) Web Development and Information Technology--impressively handled by all volunteers since 2002
7) Audit Committee, Board Governance, Facilities--handled by our Board and volunteers since 1996
8) Clerical assistance to Management--donated by an all volunteer crew--Special Projects, Donor Services, and Special Assistants
9) Grant Administration--Board oversight as well as by the Exon 20 Group leadership

ICAN salutes diversity, and our boards are comprised of: four Asians, one African, two African Americans, two Latinos/Latinas. Our councils are comprised of eleven Asians, two Latinos, and two Africans.

ICAN has made great progress in leading the way in the field of direct patient navigation services, including molecular profiling ordering, interpretation, and clinical trials sequencing strategies. The organization has expertise in clinical trials enrollment issues and retention issues.

Members of our Scientific Advisory Council continue to be the most productive drug discovery group in the world in terms of efficacy of compounds in clinical trials and FDA approvals. Our flagship Personalized Medicine Cancer Case Navigation Programs and special project known as the Exon 20 Group continue to garner praise from patients and oncologists across the country and around the world.

Success at ICAN is defined as Never Allowing a State IV Cancer Patient to be Written Off. Our patients, patient families, board and staff leadership, and the organization's many volunteers can amply testify to the fact that ICAN patient advocates work every day to achieve ICAN's aspirational goal.

How we listen

SOURCE: Self-reported by organization

Seeking feedback from people served makes programs more responsive and effective. Here’s how this organization is listening.

done We demonstrated a willingness to learn more by reviewing resources about feedback practice.
done We shared information about our current feedback practices.
  • How is your organization using feedback from the people you serve?

    To identify and remedy poor client service experiences, To identify bright spots and enhance positive service experiences, To make fundamental changes to our programs and/or operations, To inform the development of new programs/projects, To identify where we are less inclusive or equitable across demographic groups, To strengthen relationships with the people we serve, To understand people's needs and how we can help them achieve their goals

  • Which of the following feedback practices does your organization routinely carry out?

    We collect feedback from the people we serve at least annually, We take steps to get feedback from marginalized or under-represented people, We aim to collect feedback from as many people we serve as possible, We take steps to ensure people feel comfortable being honest with us, We look for patterns in feedback based on demographics (e.g., race, age, gender, etc.), We look for patterns in feedback based on people’s interactions with us (e.g., site, frequency of service, etc.), We engage the people who provide feedback in looking for ways we can improve in response, We act on the feedback we receive, We share the feedback we received with the people we serve, We tell the people who gave us feedback how we acted on their feedback, We ask the people who gave us feedback how well they think we responded

  • What challenges does the organization face when collecting feedback?

    We don't have any major challenges to collecting feedback

Financials

International Cancer Advocacy Network
lock

Unlock financial insights by subscribing to our monthly plan.

Subscribe

Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more about GuideStar Pro.

Operations

The people, governance practices, and partners that make the organization tick.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

International Cancer Advocacy Network

Board of directors
as of 03/25/2024
SOURCE: Self-reported by organization
Board chair

Ms. Sherry Weinstein

Business Owner and Community Volunteer

Term: 2024 - 2027

Marcia K Horn, JD

ICAN, International Cancer Advocacy Network

Check Website for Board and Honorary Board Updates and Consult ICAN Website for Full Council Listings

ICAN, International Cancer Advocacy Network

J.C. Gregory

Chairman, Board Governance; Event Producer

Sherry Weinstein

Chair, Board of Trustees; Community Leader

Carolyn Sechler CPA

Honorary Trustee and Treasurer Emerita

Marlene and Eugene Shapiro

Business and Community Leaders/Honorary Board

Ellen Goldstandt

Community Leader/Honorary Board

Sidney M Rosen, Esq.

Founding Chairman Emeritus; Business and Community Leader

Donna Stone

Chair, National Board of Advisors

Robert H. Tamis, MD, of cherished memory

Chairman, Physicians Council; Special Advisor, Health Information Technology; Health Care expert

Cathy Dalzell

Trustee, Tournament Co-Chair, ICAN Golf Invitational, Chair, Advisory Council, Business and Community Leader

George Robert Pettit, PhD, of cherished memory

Chairman, Scientific Advisory Council; Arizona State University Regents Professor Chemistry and Medicinal Chemistry

Cheryl J. Hintzen-Gaines

Chairman, Honorary Trustees; Community Leader and Philanthropist

Scott M. Kahn, PhD

Chairman, Biomarkers Council; Founder, Alykomed Global Solutions, Ltd., Past Member, Irving Comprehensive Cancer Center, Columbia University

Fernando Ferrer

Chairman, Ibero-American Communities Council;Business Leader

Wendy Look

ICAN National Board; Co-Chair, ICAN Golf Invitational

Robert Masyczek

Past Napa Tournament Chair; National Board of Advisors

Chuck Clayton

Chairman, Texas Board of Advisors; Texas Special Events Chairman; Member, National Board of Advisors

Andrew J Brown

Advisor, Linda Jenckes Public Policy Advocacy Program

Eric J Thompson, PhD

Vice Chairman, Biomarkers Council; Co-Chairman, Molecular Tumor Board

Robert T Hanlon, PhD

Honorary Co-Chair, International Corporate Council and Co-Founder, the Exon 20 Group at ICAN; Business and Community Leader; Author (Thermodynamics) and Senior Lecturer at MIT

Katina Bland

Chair, ICAN Speakers' Bureau and Advisor, Community Impact and Health Equity Projects

Michele Tate

Advisor, Patient Empowerment and Community Engagement

Jay Alderson

Chairman Emeritus, Board of Directors, 2000-2003

Board leadership practices

SOURCE: Self-reported by organization

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.

  • Board orientation and education
    Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? Yes
  • CEO oversight
    Has the board conducted a formal, written assessment of the chief executive within the past year ? Yes
  • Ethics and transparency
    Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? Yes
  • Board composition
    Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? Yes
  • Board performance
    Has the board conducted a formal, written self-assessment of its performance within the past three years? Yes

Organizational demographics

SOURCE: Self-reported; last updated 1/24/2024

Who works and leads organizations that serve our diverse communities? Candid partnered with CHANGE Philanthropy on this demographic section.

Leadership

The organization's leader identifies as:

Race & ethnicity
White/Caucasian/European
Gender identity
Female, Not transgender
Sexual orientation
Heterosexual or Straight
Disability status
Person without a disability

Race & ethnicity

Gender identity

Transgender Identity

Sexual orientation

No data

Disability

Equity strategies

Last updated: 08/25/2023

GuideStar partnered with Equity in the Center - an organization that works to shift mindsets, practices, and systems to increase racial equity - to create this section. Learn more

Data
  • We review compensation data across the organization (and by staff levels) to identify disparities by race.
  • We ask team members to identify racial disparities in their programs and / or portfolios.
  • We analyze disaggregated data and root causes of race disparities that impact the organization's programs, portfolios, and the populations served.
  • We disaggregate data to adjust programming goals to keep pace with changing needs of the communities we support.
  • We employ non-traditional ways of gathering feedback on programs and trainings, which may include interviews, roundtables, and external reviews with/by community stakeholders.
  • We have long-term strategic plans and measurable goals for creating a culture such that one’s race identity has no influence on how they fare within the organization.
Policies and processes
  • We use a vetting process to identify vendors and partners that share our commitment to race equity.
  • We have a promotion process that anticipates and mitigates implicit and explicit biases about people of color serving in leadership positions.
  • We seek individuals from various race backgrounds for board and executive director/CEO positions within our organization.
  • We have community representation at the board level, either on the board itself or through a community advisory board.
  • We help senior leadership understand how to be inclusive leaders with learning approaches that emphasize reflection, iteration, and adaptability.
  • We engage everyone, from the board to staff levels of the organization, in race equity work and ensure that individuals understand their roles in creating culture such that one’s race identity has no influence on how they fare within the organization.